Recursion Pharmaceuticals, Inc. (RXRX) — DEFA14A Filings
All DEFA14A filings from Recursion Pharmaceuticals, Inc.. Browse 4 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (4)
-
Recursion Pharma Files Proxy Materials
— Oct 30, 2024 Risk: low
Recursion Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on October 30, 2024. This filing relates to the company's solicitation o -
Recursion Pharma Files Proxy Solicitation Material
— Sep 19, 2024 Risk: low
Recursion Pharmaceuticals, Inc. filed a DEFA14A on September 19, 2024, related to soliciting materials under Rule 14a-12. The filing indicates no fee was requir -
Recursion Pharma Files Proxy Statement, No Fee
— Sep 4, 2024 Risk: low
Recursion Pharmaceuticals, Inc. filed a DEFA14A proxy statement on September 4, 2024, indicating it is soliciting materials under Rule 14a-12. The filing does n -
Recursion Pharma Files Proxy Statement
— Aug 9, 2024 Risk: low
Recursion Pharmaceuticals, Inc. filed a DEFA14A proxy statement on August 9, 2024, indicating it is soliciting materials under Rule 14a-12. The company, incorpo
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX